Targeting tumours with novel radiopharmaceuticals
European Pharmaceutical Review
OCTOBER 19, 2023
How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? This has been demonstrated recently with PLUVICTO ® , which was the first US Food and Drug Administration (FDA)-approved targeted radioligand therapy for eligible patients with prostate cancer.
Let's personalize your content